Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis

Next Previous
Search
Trial Profile

A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RVT-3101 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Tuscany 2
  • Sponsors Roche; Telavant

    • Most Recent Events

    • 21 Oct 2023 This trial has been completed in Spain according to European Clinical Trials Database record.
    • 22 Jun 2023 Results from the chronic period presented in the Roivant Sciences Media Release.
    • 21 Jun 2023 According to a Roivant Sciences media release, the company will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 (anti-TL1A antibody) in ulcerative colitis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top